Page last updated: 2024-11-13
gonyautoxin v
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
gonyautoxin V: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 49789073 |
| CHEMBL ID | 496271 |
| CHEBI ID | 138870 |
| MeSH ID | M0124643 |
Synonyms (19)
| Synonym |
|---|
| gonyautoxin v |
| CHEBI:138870 |
| gonyautoxin 5 |
| ({[(3as,4r,10as)-2,6-diamino-10,10-dihydroxy-3a,4,9,10-tetrahydro-3h,8h-pyrrolo[1,2-c]purin-4-yl]methoxy}carbonyl)sulfamic acid |
| 64296-25-9 |
| CHEMBL496271 |
| gtx5 |
| C20018 |
| 122139-78-0 |
| gonyautoxin-v |
| carbamic acid, sulfo-, c-((2,6-diamino-3a,4,9,10-tetrahydro-10,10-dihydroxy-1h,8h-pyrrolo(1,2-c)purin-4-yl)methyl) ester, (3as-(3aalpha,4alpha,10ar*))- |
| 3833h3turf , |
| unii-3833h3turf |
| carbamic acid, sulfo-, c-(((3as,4r,10as)-2,6-diamino-3a,4,9,10-tetrahydro-10,10-dihydroxy-1h,8h-pyrrolo(1,2-c)purin-4-yl)methyl) ester |
| ((3as,4r,10as)-2,6-diamino-10,10-dihydroxy-3a,4,8,9-tetrahydro-3h-pyrrolo(1,2-c)purin-4-yl)methoxycarbonylsulfamic acid |
| DTXSID60214520 |
| gonyautoxin-5 |
| Q27256732 |
| [(3as,4r,10as)-2,6-diamino-10,10-dihydroxy-3a,4,8,9-tetrahydro-1h-pyrrolo[1,2-c]purin-4-yl]methoxycarbonylsulfamic acid |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Roles (1)
| Role | Description |
|---|---|
| marine metabolite | Any metabolite produced during a metabolic reaction in marine macro- and microorganisms. |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
Drug Classes (2)
| Class | Description |
|---|---|
| organic heterotricyclic compound | An organic tricyclic compound in which at least one of the rings of the tricyclic skeleton contains one or more heteroatoms. |
| paralytic shellfish toxin | |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
Bioassays (1)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID362645 | Toxicity in mouse at 160 MU/umol, ip | 2008 | Journal of natural products, Sep, Volume: 71, Issue:9 | Isolation and structure elucidation of new and unusual saxitoxin analogues from mussels. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (7)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 3 (42.86) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 3 (42.86) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 12.72
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.72) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 1 (14.29%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 6 (85.71%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||